GlassScriptPhysician profile
Luette S Semmes
NPI 1962437590
$19,409.10
in general payments reported to CMS, 2019-2025
35 companies · $3,371 in 2025
The $3,371 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,673 · 2020: $1,267 · 2021: $2,292 · 2022: $3,248 · 2023: $3,719 · 2024: $3,840 · 2025: $3,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,781.53 |
| Education | $147.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,466.54 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Janssen Biotech, INC. | $2,141.85 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $1,840.81 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $1,581.01 | 2021-2025 | Adbry, Anzupgo |
| Amgen INC. | $1,428.13 | 2020-2025 | Otezla, Enbrel, Otezla |
| Sun Pharmaceutical Industries INC. | $1,241.14 | 2019-2025 | Ilumya, Blu-U, Odomzo |
| Dermavant Sciences, INC. | $1,053.83 | 2022-2024 | Vtama |
| Genzyme Corporation | $1,033.67 | 2019-2025 | |
| Pfizer INC. | $966.48 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $868.72 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $567.24 | 2019-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $524.92 | 2021-2025 | Sotyktu |
| Incyte Corporation | $321.33 | 2021-2025 | Opzelura |
| Ucb, INC. | $309.55 | 2019-2025 | Bimzelx, Cimzia |
| Organon LLC | $302.08 | 2025 | Vtama |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luette Semmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.